Patients are asking for an alternative to medications

- 48% of patients on BPH medications do not have clinically significant symptom improvement.1
- Drugs can have serious side effects. Clinical results show a 14%, 19% and 23% increase in impotence for Doxazosin, Finasteride and Combination Therapy, respectively.2
- 77% of all patients surveyed are interested in having an in-office procedure.3

Urologix has the answer with Cooled ThermoTherapy™ and Prostiva® RF Therapy

- Both procedures provide clinically significant QOL, flow rate and symptom score improvement with greater than an 11 point improvement in AUASS in the first year2,3.
- Cooled ThermoTherapy and Prostiva provide durable results without retreatment at 5 years in over 90% and 86% of patients, respectively2,3.
- Between the two Urologix therapies, most prostate anatomies can be treated including prostate sizes up to 100g with Cooled ThermoTherapy and asymmetric glands, median lobes, and short lobes with Prostiva.

To learn more about Urologix products and services, please call us at (888) 229-0772 or visit www.urologix.com

5 Data from online survey conducted by Harris Interactive, August 2007 sponsored by Medtronic, Inc. Survey included 206 qualified respondents.
**Prostiva® RF Therapy**

- Reaches intraprostatic temperatures of 110°C allowing it to create a lesion in the tissue, causing effective tissue ablation, in just 2 minutes and 20 seconds while preserving the urethra.

- Experienced physicians have stated that they achieve excellent patient tolerability when utilizing recent advances in prostate block techniques.

- Direct visualization and precision allows treatment of median and lateral lobes as well as asymmetrical prostates.

- Ability to create a predictable prostate defect without resection of tissue.

- Effective therapy – clinically significant improvements in IPSS, peak uroflow, and quality of life at five years.

- Durable results – reintervention not necessary in over 86% of patients at five years.

- Low rate of side effects.

**Cooled ThermoTherapy**

- Reaches intraprostatic temperatures of 80°C causing effective tissue ablation in just a 28.5 minute treatment while preserving the urethra.

- Advanced three chamber proprietary cooling technology provides enhanced urethral preservation and patient comfort.

- Multiple catheter sizes and a high-energy delivery system provide physicians with customizable treatment options for glands up to 100 gm.

- Ability to create a predictable prostate defect without resection of tissue.

- Effective therapy – clinically significant improvements in IPSS, peak uroflow, and quality of life at five years.

- Durable results – reintervention not necessary in over 90% of patients at five years.

- Low rate of side effects.

---

**REFERENCES**

1. Data derived from the Prostiva RF Therapy System User Guide 8930 CRMRef_R06
2. Physician statements are anecdotal and not based on clinical study results. Physician reports are on file at Urologix.
3. Data on file at Urologix, Inc.
5. Data derived from the CTC Advance® Instructions for Use, 250348 Rev D 08/10

---

**INDICATIONS**

- **Prostiva RF Therapy** Cooled ThermoTherapy is indicated to relieve symptoms and obstruction associated with BPH in men with prostatic urethra lengths greater than or equal to 2.5 cm.

- **Cooled ThermoTherapy** is indicated to relieve symptoms and obstruction associated with BPH in men with prostatic urethra lengths greater than or equal to 2.5 cm.

---

**Contraindications**

- This treatment is contraindicated for patients with a prostatic urethra <2.5 cm in length as measured from the bladder neck to the verumontanum, with urethral stricture (unable to pass 22F urethroscope), peripheral arterial disease with intermittent claudication or Leriches Syndrome (i.e. claudication of the buttocks or perineum); patients who have undergone pelvic radiation therapy or have implanted active devices, including pacemakers or defibrillators within 2.6 inches (6.5 cm) of the prostatic urethra.

---

**Caution:**

- Federal (U.S.A.) law restricts this device by or on the order of a physician trained and/or experienced in the use of this device. For more complete information and instructions, see the Prostiva RF Therapy System Manual at www.urologix.com.
As seen in the

Urologix Highlights BPH In-Office Treatment in The Journal of Urology®

As seen in The

lower urinary tract symptoms. Medications have an option for men experiencing moderate to severe symptoms.

77% of BPH patients are interested in having an in-office procedure.

50% are not satisfied with the effectiveness of their medications.

77% of BPH patients are interested in having an in-office procedure.

61% of patients currently on medication would actually prefer an in-office procedure.

A Growing Problem

As the world continues to grow and age, BPH is becoming a much more prevalent issue for our male population. Urologix is leading the way toward in-office therapies with Cooled ThermoTherapy® (CTT) and Prostiva® RF Therapy, providing real alternatives to traditional medication-based options.

Benign Prostate Hyperplasia (BPH) is a common and costly condition impacting millions of men worldwide. Nearly 50% of men over the age of 50 report symptoms of BPH, and occurrence increases with advancing age.1 Today, medical management is by far the most prevalent treatment of choice. However, if you look at BPH drugs objectively, they may not be the best option for men experiencing moderate or severe lower urinary tract symptoms. Medications need to be taken daily and indefensibly and are not as effective as in-office and surgical therapies.2 Drugs also have been shown to cause significant side effects including fatigue, dizziness, ejaculation disorders, impotence, loss of sexual drive, or breast disorders.3 In fact, treatment efficacy rarely leads to a level of improvement the patients would rate as excellent or very good. It is not surprising that with less than ideal efficacy and common side effects, compliance with medication is a serious concern.4

So what other treatment options may be a better choice for the BPH Patient? Let’s consider In-Office BPH Therapy.

Do Patients Want In-Office Therapies?

Research shows that BPH patients aren’t satisfied with taking chronic BPH medication for life. The Prostate Research Study completed by the Harris Interactive Group in 2007 showed that of patients surveyed:

• 50% are not satisfied with the effectiveness of their medication5

• 77% of BPH patients are interested in having an in-office procedure6

• 61% of patients currently on medication would actually prefer an in-office procedure7

Is BPH In-Office Therapy Effective?

Clinical research has demonstrated that both CTT and Prostiva are effective in the treatment of BPH.8,9

<table>
<thead>
<tr>
<th>Procedure</th>
<th>1 Year</th>
<th>4 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>TURP</td>
<td>10.2</td>
<td>10.1</td>
</tr>
<tr>
<td>Cooled ThermoTherapy</td>
<td>7.9</td>
<td>7.7</td>
</tr>
<tr>
<td>Prostiva</td>
<td>7.5</td>
<td>7.2</td>
</tr>
<tr>
<td>Combination</td>
<td>7.3</td>
<td>6.6</td>
</tr>
<tr>
<td>Fastrida</td>
<td>6.2</td>
<td>5.9</td>
</tr>
<tr>
<td>Alpha Blockers</td>
<td>7.0</td>
<td>7.6</td>
</tr>
</tbody>
</table>

It is important to note that those data points were not collected in a head-to-head study, therefore, direct comparisons cannot be made. BPH Medication data is derived from the Contum™ Study (see reference 7). Cooled ThermoTherapy data is derived from Mynderse, et al. 2011 (see reference 8), and Prostiva RF Therapy data is derived from Hs, et al. 2004 (see reference 9).

Is BPH In-Office Therapy Durable?

Clinical trials and improved cooling technologies, controlling the patient’s comfort level has greatly improved over the past 10 years. However, it is important to use a thoughtful pain management approach when performing in-office treatments. Many experienced physicians use pre-procedure oral medications, local anesthesia, and prostatic block techniques to maximize patient comfort.

In a recent clinical study, pain levels were measured using a 0-10 VAS score and demonstrated an average score of <3 throughout the Cooled ThermoTherapy procedure.8

What are the Benefits of In-Office BPH Therapy?

In-Office BPH Therapy provides significant benefits to both the healthcare professional and the patient.

• Minimally invasive treatment which does not require general anesthesia

• Convenient treatment completed in your office in less than an hour

• Clinically proven results which typically last up to 5 years8

• Durability with very small retreatment rates9,10

• Low rate of side effects9,10

• Established reimbursement

Is BPH In-Office Therapy Difficult to Integrate into My Practice?

In today’s busy practices, introducing a new technology into your office can be a daunting task. Urologix provides services and tools that make that integration seamless.

“Minimally invasive therapies are significantly more effective for relief of lower urinary tract symptoms than pharmacologic therapy as demonstrated in randomized clinical trials. Moreover, durability for both Cooled Thermotherapy and Prostiva are well documented in the literature. Since 1998, I have treated more than 800 patients with Cooled Thermotherapy and the retreatment rate for my patients after 14 years is only 14%. I believe that minimally invasive therapies for patients with symptomatic BPH should be the primary therapy because they provide more significant symptom relief and have durable results.” — Robert G. Pugh, MD

References:


2. 50% of men over the age of 50 report symptoms of BPH, and occurrence increases with advancing age.

3. Drugs also have been shown to cause significant side effects including fatigue, dizziness, ejaculation disorders, impotence, loss of sex drive, or breast disorders.

4. In fact, treatment efficacy rarely leads to a level of improvement the patients would rate as excellent or very good.

5. It is not surprising that with less than ideal efficacy and common side effects, compliance with medication is a serious concern.

6. So what other treatment options may be a better choice for the BPH Patient? Let’s consider In-Office BPH Therapy.

7. Researchers have shown that BPH patients aren’t satisfied with taking chronic BPH medication for life.

8. The Prostate Research Study completed by the Harris Interactive Group in 2007 showed that of patients surveyed:

9. 50% are not satisfied with the effectiveness of their medication.

10. 77% of BPH patients are interested in having an in-office procedure.

11. 61% of patients currently on medication would actually prefer an in-office procedure.

For more information, please call the Urologix Customer Support team at (888) 229-0772 or visit www.urologix.com.